

REMARKS

Claims 1, 3 to 13, and 25 to 28 are in the application. Claims 2 and 14 have been cancelled. Claims 1 and 13 have been amended. Support for the amendments lie in the claims as originally filed. The subject matter of claims 2 and 14 has been added to claims 1 and 13 respectively. No new matter is believed added.

The Examiner has asked for an election of species. Applicants elect the imidazole of independent claims 1, 13 and 28 to be miconazole.

Applicants further elect, if necessary, the carrier to be petrolatum.

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned at the number below. It is not believed that this paper should cause any additional fees or charges to be required, other than expressly provided for already. However, if this is not the case, the Commissioner is hereby authorized to charge Deposit account 19-2570 accordingly.

Respectfully submitted,

/ Dara L Dinner/

Dara L. Dinner
Attorney for Applicants
Registration No. 33,680

GlaxoSmithKline, LLC
Global Patents- UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270- 5017
Facsimile (610) 270-5090